Developing drug therapies in bronchiectasis

Bibliography

• Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010(65 Suppl 1):i1-58
   Google Scholar
• Bilton D, Jones AL. Chapter 1: bronchiectasis: epidemiology and causes. In: Floto RA, Haworth CS, editors. Bronchiectasis. European Respiratory Society; Lausanne, Switzerland: 2011. Published online May 26, 2011; 10.1183/1025448x.10003110
   Google Scholar
• Weycker D, Edelsberg J, Oster G, et al. Prevalence and economic burden of bronchiectasis. Clin Pulm Med 2005;12(4):205-9
   Google Scholar
• Reid LM. Reduction in bronchial subdivision in bronchiectasis. Thorax 1950;5(3):233-47
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Smith MP, McHugh BJ, et al. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2012;186(7):657-65
   PubMed Web of Science ®Google Scholar
• O’Donnell AE. Bronchiectasis. CHEST J 2008;134(4):815-23
   PubMed Web of Science ®Google Scholar
• Kelly MG, Murphy S, Elborn JS. Bronchiectasis in secondary care: a comprehensive profile of a neglected disease. Eur J Intern Med 2003;14(8):488-92
   PubMedGoogle Scholar
• Nicotra MB, Rivera M, Dale AM, et al. Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest 1995;108(4):955-61
   PubMed Web of Science ®Google Scholar
• Cole P. Host-microbe relationships in chronic respiratory infection. Respiration 1989(55 Suppl 1):5-8
   PubMedGoogle Scholar
• Angrill J, Agusti C, de Celis R, et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002;57(1):15-19
   PubMed Web of Science ®Google Scholar
• Hill AT, Welham S, Reid K, Bucknall CE. British thoracic society national bronchiectasis audit 2010 and 2011. Thorax 2012;67:928-30
   PubMed Web of Science ®Google Scholar
• Wilson CB, Jones PW, O’Leary CJ, et al. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J 1997;10(8):1754-60
   PubMed Web of Science ®Google Scholar
• Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M, et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007;132(5):1565-72
   PubMed Web of Science ®Google Scholar
• Evans SA, Turner SM, Bosch BJ, et al. Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. Eur Respir J 1996;9(8):1601-4
   PubMed Web of Science ®Google Scholar
• MacLeod DL, Barker LM, Sutherland JL, et al. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J Antimicrob Chemother 2009;64(4):829-36
   PubMed Web of Science ®Google Scholar
• O’Donnell AE, Swarnakar R, Yahina L, et al. A placebo-controlled study of liposomal amikacin for inhalation nebulized once daily in the treatment of bronchiectatic patients with chronic Pseudomonas aeruginosa lung infection. Eur Respir J 2009;34:231S
   PubMedGoogle Scholar
• Hill A, Bilton D, Brown J, et al. British thoracic society quality standards for clinically significant bronchiectasis in adults July 2012. Br Thorac Soc Rep 2012;4:1-16
   Google Scholar
• Malakhov MP, Aschenbrenner LM, Smee DF, et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother 2006;50:1470-9
   PubMed Web of Science ®Google Scholar
• Nicholls JM, Aschenbrenner LM, Paulson JC, et al. Comment on: concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza. J Antimicrob Chemother 2008;62:426-8
   PubMed Web of Science ®Google Scholar
• Triana-Baltzer GB, Gubareva LV, Nicholls JM, et al. Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181; a sialidase fusion protein. PLoS One 2009;4(11):e7788
   PubMed Web of Science ®Google Scholar
• Emmerich B, Emslander HP, Pachmann K, et al. Local immunity in patients with chronic bronchitis and the effects of a bacterial extract, Bronco-AvxomR, on T-lymphocytes, macrophages, gamma-interferon and secretory immunoglobulin A in bronchoalveolar lavage fluid and other variables. Respiration 1990;57:90-9
   PubMed Web of Science ®Google Scholar
• Collet JP, Shapiro P, Ernst P, et al. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant. Am J Respir Crit Care Med 1997;156(6):1719-24
   PubMed Web of Science ®Google Scholar
• Orcel B, Delclaux B, Baud M, et al. Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis. Eur Respir J 1994;7(3):446-52
   PubMed Web of Science ®Google Scholar
• Soler M, Mutterlein R, Cozma G. Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease. Respiration 2007;74(1):26-32
   PubMed Web of Science ®Google Scholar
• Sadowska A, Verbraecken J, Darquennes K, De Backer WA. Role of N-acetylcysteine in the management of COPD. Int J Chron Obstruct Pulmon Dis 2006;1(4):425-34
   PubMedGoogle Scholar
• Zheng JP, Wen FQ, Bai CX, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med 2014;2(3):187-94
   PubMed Web of Science ®Google Scholar
• Turner RD, Bothamley GH. N-acetylcysteine for COPD: the evidence remains inconclusive. Lancet Respir Med 2014;2(4):e3
   Google Scholar
• Vandermeer ML, Thomas AR, Kamimoto L, et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis 2012;205(1):13-19
   PubMed Web of Science ®Google Scholar
• Shyamsundar M, McKeown ST, O’Kane CM, et al. Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med 2009;179(12):1107-14
   PubMed Web of Science ®Google Scholar
• Mandal P, Chalmers JD, Graham C, et al. Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial. Lancet Respir Med 2014;2(6):455-63
   PubMed Web of Science ®Google Scholar
• www.nice.org.uk/asthma
   Google Scholar
• Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma. Am J Respir Crit Care Med 2007;175(3):235-42
   PubMed Web of Science ®Google Scholar
• Ito K, Lim S, Caramori G, et al. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA 2002;99(13):8921-6
   PubMed Web of Science ®Google Scholar
• Milara J, Lluch J, Almudever P, et al. Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2014;134(2):314-22
   PubMed Web of Science ®Google Scholar
• Llewellyn-Jones CG, Johnson MM, Mitchell JL, et al. In vivo study of indomethacin in bronchiectasis: effect on neutrophil function and lung secretion. Eur Respir J 1995;8(9):1479-87
   PubMed Web of Science ®Google Scholar
• Stockley R, De Soyza A, Gunawardena K, et al. Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis. Respir Med 2013;107(4):524-33
   PubMed Web of Science ®Google Scholar
• Cobanoglu N, Ozcelik U, Gocmen A, et al. Antioxidant effect of beta-carotene in cystic fibrosis and bronchiectasis: clinical and laboratory parameters of a pilot study. Acta Paediatrica 2002;91(7):793-8
   PubMed Web of Science ®Google Scholar
• Kellett F, Redfern J, Niven RM. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. Respir Med 2005;99(1):27-31
   PubMed Web of Science ®Google Scholar
• Kellett F, Robert NM. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir Med 2011;105(12):1831-5
   PubMed Web of Science ®Google Scholar
• Nicolson CH, Stirling RG, Borg BM, et al. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med 2012;106(5):661-7
   PubMed Web of Science ®Google Scholar
• Daviskas E, Anderson SD, Gomes K, et al. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirology (Carlton, Vic) 2005;10(1):46-56
   PubMed Web of Science ®Google Scholar
• Daviskas E, Anderson SD, Eberl S, et al. Effect of increasing doses of mannitol on mucus clearance in patients with bronchiectasis. Eur Respir J 2008;31(4):765-72
   PubMed Web of Science ®Google Scholar
• Bilton D, Daviskas E, Anderson SD, et al. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest 2013;144(1):215-25
   PubMed Web of Science ®Google Scholar
• Daviskas E, Anderson SD, Eberl S, et al. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am J Respir Crit Care Med 1999;159(6):1843-8
   PubMed Web of Science ®Google Scholar
• Daviskas E, Anderson SD, Gomes K. Increase in health status after 12 days treatment with inhaled mannitol in patients with bronchiectasis. Eur Respir J 2003;22:Suppl 45:p. 430
   Google Scholar
• Daviskas E, Anderson SD, Eberl S, et al. The 24-h effect of mannitol on the clearance of mucus in patients with bronchiectasis. Chest 2001;119(2):414-21
   PubMed Web of Science ®Google Scholar
• Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012;380(9842):660-7
   PubMed Web of Science ®Google Scholar
• Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013;309(12):1260-7
   PubMed Web of Science ®Google Scholar
• Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013;309(12):1251-9
   PubMed Web of Science ®Google Scholar
• Murray MP, Govan JR, Doherty CJ, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011;183(4):491-9
   PubMed Web of Science ®Google Scholar
• Haworth CS, Foweraker JE, Wilkinson P, et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014;189(8):975-82
   PubMed Web of Science ®Google Scholar
• Barker AF, O’Donnell AE, Flume P, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med 2014;2(9):738-49
   PubMed Web of Science ®Google Scholar
• Mandal P, Sidhu MK, Donaldson LS, et al. Eight-weekly intravenous antibiotics is beneficial in severe bronchiectasis. QJM 2013;106(1):27-33
   PubMed Web of Science ®Google Scholar
• O’Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human dnase. Chest 1998;113:1329-34
   PubMed Web of Science ®Google Scholar
• Wilson R, Welte T, Polverino E, et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J 2013;41(5):1107-15
   PubMed Web of Science ®Google Scholar
• Serisier DJ, Bilton D, De Soyza A, et al. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013;68(9):812-17
   PubMed Web of Science ®Google Scholar
• Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000;162(2 Pt 1):481-5
   PubMed Web of Science ®Google Scholar
• Drobnic ME, Sune P, Montoro JB, et al. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005;39(1):39-44
   PubMed Web of Science ®Google Scholar
• Bilton D, Henig N, Morrissey B, et al. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006;130(5):1503-10
   PubMed Web of Science ®Google Scholar
• Tamaoki J, Chiyotani A, Kobayashi K, et al. Effect of indomethacin on bronchorrhea in patients with chronic bronchitis, diffuse panbronchiolitis, or bronchiectasis. Am Rev Respir Dis 1992;145(3):548-52
   PubMed Web of Science ®Google Scholar